or Try an Advanced Search...

    ETF Components for CANC - Tema Oncology ETF


    Below is a list of stocks held by this ETF. We only list holdings in the same market. If this is a global ETF, there may be additional components other than those listed here.

    Holdings

    Symbol Grade Price % Change Allocation
    GILD B 0.17 5.49
    REGN F -0.14 5.25
    RVMD B 1.13 4.60
    ARGX A -0.25 4.19
    ILMN C 1.19 4.16
    INCY C -1.58 4.10
    BPMC C 0.79 4.05
    EXEL B -0.13 2.93
    MRK F 0.59 2.81
    AGIO C -0.59 2.71
    MREO F 0.00 2.54
    AMGN D -0.35 2.37
    BGNE D -0.75 2.30
    CRSP D -2.45 2.30
    SWTX C -1.38 2.14
    GH B 0.07 2.07
    NVS D 0.35 2.03
    NUVL D 1.73 1.99
    DAWN D -1.69 1.90
    GMAB F 0.34 1.84
    NTLA F 5.95 1.58
    ACLX C 0.45 1.50
    EXAS D 1.67 1.45
    CLDX D 1.78 1.44
    SDGR C -0.97 1.44
    JANX C -3.37 1.43
    LEGN D -0.97 1.41
    MRUS F 2.10 1.37
    LNTH C 0.47 1.22
    NRIX C 0.00 1.15
    COGT D 1.32 0.95
    IDYA F 1.84 0.90
    BNTX D 1.48 0.89
    BCYC F -0.98 0.84
    CGEM F -2.70 0.83
    ORIC F -0.46 0.76
    MRNA F -0.30 0.72
    RLAY F -1.50 0.69
    IMCR C -0.35 0.69
    RCUS F -1.85 0.67
    TERN F 0.71 0.60
    CGON F -0.40 0.56
    ARVN F 2.78 0.46

    Represented by ETF Holdings

    Keywords: Cancer Biopharmaceutical Medicine Biotechnology Clinical Medicine Solid Tumors Immunology Disease Life Sciences Monoclonal Antibodies Nasdaq 100 Precision Medicine S&P 500 Acute Myeloid Leukemia Biology Drug Discovery Enzymes Genetics Immune System Immunotherapies
    Industries: Biotechnology Diagnostics & Research Drug Manufacturers - Major Health Information Services Long-Term Care Facilities

    Recent News for Tema Oncology ETF & its Holdings

    Date Stock Title
    Nov 21 SDGR Schrödinger: Positive Signs Despite The Share Price Decline
    Nov 21 CRSP CRISPR Therapeutics AG (CRSP) Jefferies London Healthcare Conference (Transcript)
    Nov 20 LNTH Why Lantheus Holdings Stock Won Big on Wednesday
    Nov 20 ILMN Myriad Genetics Announces Incorporation of its Proprietary HRD platform in Illumina’s Updated Comprehensive Gene Panel Assay, TruSight™ Oncology 500 v2
    Nov 20 DAWN Day One Announces Retirement of Dr. Samuel Blackman, Co-Founder and Head of Research & Development
    Nov 20 AMGN AMGEN ANNOUNCES SENIOR EXECUTIVE RESEARCH APPOINTMENT
    Nov 20 NRIX Nurix Therapeutics Receives PRIME Designation from the European Medicines Agency for NX-5948 for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia
    Nov 20 ILMN If RFK Jr. Cuts Science Funding, These Instrument Makers May Suffer
    Nov 20 MRNA CDC warns of an imminent spike in COVID, flu cases
    Nov 20 MRK Merck Foundation Announces $17 Million U.S. Initiative To Expand Access to High-Quality Cardiac Care
    Nov 20 GH Guardant Health Stock Sees RS Rating Jump To 83
    Nov 20 MRK Merck & Co., Inc. (MRK)’s Blockbuster Drugs: A Key Player in Ken Griffin’s Portfolio
    Nov 20 ILMN Illumina, Inc. (ILMN) CFO Ankur Dhingra Hosts Wolfe Research 2024 Healthcare Conference (Transcript)
    Nov 20 SWTX SpringWorks started at outperform by Evercore ahead of FDA decision
    Nov 20 GH Guardant Health: Focused On Future Growth, Hold
    Nov 20 GILD Gilead Sciences, Inc. (GILD) Jefferies London Healthcare Conference (Transcript)
    Nov 20 AMGN SLN Stock Down Despite Cholesterol Drug Lowering Lipoprotein Levels
    Nov 20 RLAY Down -27.93% in 4 Weeks, Here's Why Relay Therapeutics (RLAY) Looks Ripe for a Turnaround
    Nov 20 CRSP CRISPR Therapeutics Stock Falls 7% in Two Weeks: Time to Hold or Sell?
    Nov 20 SDGR Schrödinger to Present at Piper Sandler 36th Annual Healthcare Conference
    Under normal circumstances, the fund seeks to achieve its investment objective by investing at least 80% of its net assets, which include borrowings for investment purposes, in publicly listed companies that derive at least 50% of revenues from oncology. The fund is non-diversified.
    Index Fund Investment Management Private Equity
    Back to the Main CANC Page...